Alemtuzumab (MabCampath®) is a humanized rat monoclonal antibody that targets the CD52 antigen. It has been approved for the treatment of patients with resistant chronic lymphocytic leukaemia (CLL).
| PubMed | eMedicine | OMIM | Google | Google images | Yahoo images | YouTube |
- Printer friendly version